Document Detail


Characteristic response of astrocytes to plasminogen/plasmin to upregulate transforming growth factor beta 3 (TGFbeta3) production/secretion through proteinase-activated receptor-1 (PAR-1) and the downstream phosphatidylinositol 3-kinase (PI3K)-Akt/PKB signaling cascade.
MedLine Citation:
PMID:  19765562     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of microglia-derived plasminogen (PLGn) on the neurotrophic role of astrocytes were investigated in vitro. The treatment of astrocytes with rat PLGn led to a significant increase in transforming growth factor beta3 (TGFbeta3) in the conditioned medium (CM). This response of astrocytes to PLGn was characteristic and different from that to other stimulators, including lipopolysaccharide, phorbol-12-myristate-13-acetate, interferon-gamma, and ATP. In surveying the signaling molecules that respond to PLGn in astrocytes, we found that Akt/PKB phosphorylation is promoted. The pretreatment of astrocytes with an Akt inhibitor prior to PLGn stimulation resulted in a significant decrease in TGFbeta3 amounts in the CM, suggesting an association of Akt with TGFbeta3 production/secretion. Further survey revealed that phosphatidylinositol 3 kinase (PI3K) is closely associated with TGFbeta3 production/secretion in astrocytes. In fact, PI3K inhibitor clearly depressed the phosphorylation of Akt, indicating that PI3K is localized upstream of Akt. Moreover, the effects of PLGn to increase TGFbeta3 were depressed by pretreatment with a proteinase-activated receptor-1 (PAR-1) inhibitor. Plasmin could mimic the PLGn effects to upregulate TGFbeta3, and the plasmin effects were suppressed by pretreatment with the PAR-1 inhibitor, suggesting the association of PLGn/plasmin effects with PAR-1. In addition, Akt phosphorylation caused by plasmin was inhibited in the presence of PAR-1 inhibitor. We have therefore demonstrated that PLGn/plasmin, probably plasmin, facilitates the production/secretion of TGFbeta3 in astrocytes through both PAR-1 and the subsequent signaling cascade including PI3K and Akt.
Authors:
Shyuichi Maeda; Kazuyuki Nakajima; Yoko Tohyama; Shinichi Kohsaka
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-09-16
Journal Detail:
Title:  Brain research     Volume:  1305     ISSN:  1872-6240     ISO Abbreviation:  Brain Res.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-25     Completed Date:  2010-01-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0045503     Medline TA:  Brain Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1-13     Citation Subset:  IM    
Affiliation:
Department of Bioinformatics, Faculty of Engineering, Soka University, 1-236 Tangi-machi, Hachioji, Tokyo 192-8577, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
1-Phosphatidylinositol 3-Kinase / metabolism*
Analysis of Variance
Animals
Astrocytes / drug effects,  metabolism*
Blotting, Western
Cells, Cultured
Chromones / pharmacology
Culture Media, Conditioned
Dose-Response Relationship, Drug
Enzyme Inhibitors / pharmacology
Fibrinolysin / metabolism*,  pharmacology
Fibrinolytic Agents / pharmacology
Fibroblast Growth Factors / metabolism
Flavonoids / pharmacology
Immunohistochemistry
Microglia / metabolism
Morpholines / pharmacology
Nerve Growth Factors / metabolism
Neurons / metabolism
Phosphorylation / drug effects
Plasminogen / metabolism*,  pharmacology
Proto-Oncogene Proteins c-akt / metabolism*
Pyrroles / pharmacology
Quinazolines / pharmacology
RNA, Messenger / metabolism
Rats
Receptor, PAR-1 / metabolism*
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction / drug effects,  physiology
Transforming Growth Factor beta3 / metabolism*
Chemical
Reg. No./Substance:
0/Chromones; 0/Culture Media, Conditioned; 0/Enzyme Inhibitors; 0/Fibrinolytic Agents; 0/Flavonoids; 0/Morpholines; 0/N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine; 0/Nerve Growth Factors; 0/PD 98059; 0/Pyrroles; 0/Quinazolines; 0/RNA, Messenger; 0/Receptor, PAR-1; 0/Transforming Growth Factor beta3; 154447-36-6/2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 62031-54-3/Fibroblast Growth Factors; 9001-91-6/Plasminogen; EC 2.7.1.137/1-Phosphatidylinositol 3-Kinase; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; EC 3.4.21.7/Fibrinolysin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Attentional processes and blood lactate levels.
Next Document:  Marine compound Xyloketal B protects PC12 cells against OGD-induced cell damage.